However, the activity of the non-glycosylated TRPV N358Q mutant was not altered in the presence of β-gal, showing that the stimulation is dependent on the presence of the TRPV5 N-glycan. In addition, β-gal was found to stimulate transcellular Ca 2+ transport in isolated mouse primary DCT2/CNT cells. β-gal expression was detected in the apical membrane of the proximal tubules and the protein was found in mouse urine. In summary, β-gal is present in the pro-urine from where it is thought to stimulate TRPV5 activity.
Introduction
The extracellular calcium (Ca 2+ ) concentration is tightly regulated due to the critical role Ca 2+ plays in numerous signalling cascades, muscle contraction and bone mineralization (Felsenfeld et al. 2013) . The transient receptor potential vanilloid type 5 (TRPV5) channel mediates the apical entry of Ca 2+ into the kidney epithelial cell;
this constitutes a finely regulated rate-limiting step in renal Ca 2+ reabsorption (Renkema et al. 2005; van de Graaf et al. 2006) . TRPV5 is expressed in the epithelial cells of the late distal convoluted tubule (DCT2) and connecting tubule (CNT) segments of the nephron, where it mediates ~5-10% of the total Ca 2+ reabsorption in the kidney Dimke et al. 2011 ). The channel is regulated by a variety of factors including 1,25-dihydroxyvitamin D 3 , parathyroid hormone, dietary Ca 2+ , and acid/base status (de Groot et al. 2008) .
Each subunit of the tetrameric TRPV5 channel contains an intracellular carboxy-and amino-terminus, and six transmembrane segments. TRPV5 possesses a single Nglycan on the Asn358 (N358) amino acid located in the extracellular loop between the first and second transmembrane domain. This glycan plays an important role in the regulation of the TRPV5 channel expression at the plasma membrane (Chang et al. 2005; Cha et al. 2008; Leunissen et al. 2013) .
Given that approximately 50% of the proteome is glycosylated, it is one of the most common post-translational modifications in eukaryotic cells (Apweiler et al. 1999) . Extracellular N-glycans of plasma membrane glycoproteins are involved in various signalling processes, such as apoptosis and cell-cell contact (Varki et al. 2009 ). Mammalian extracellular glycosidases modify the structure of cell surface glycans by hydrolyzing specific sugars (Cummings and Pierce 2014) . For example, sialidase (also known as neuraminidase) hydrolyzes terminal sialic acids from Nglycans and gangliolipids (Parker and J.J. Kohler 2010) , while β-galactosidase (β-gal) hydrolyzes galactose units (Varki et al. 2009 ). Modification of the glycan of proteins can alter substrate binding, enzymatic activity or protein stability at the plasma membrane (Varki et al. 2009; Nagae and Yamaguchi 2012) .
Previous studies have shown that glycosidases influence TRPV5 channel activity via the N-glycan. For instance, the putative pro-urinary glycosidase klotho stabilizes TRPV5 at the plasma membrane, an effect that is absent in the non-glycosylated N358Q mutant (Chang et al. 2005; Cha et al. 2008; Leunissen et al. 2013) . A different glycosidase, β-gal, is present in its active form in the urine of human subjects (G. Xu et al. 1999 ). Deficiencies of β-gal are the cause of human metabolic disorders such as GM1 gangliosidosis (OMIM nr.230500) and Morquio B disease (OMIM nr.253010), both characterized by heterogeneous clinical phenotypes (Oshima et al. 1991; Yoshida et al. 1992) . These patients often present with bone malformations.
Interestingly, TRPV5 knockout (-/-) mice also exhibit significant disturbances in bone structure .
We hypothesized that β-gal regulates the activity of TRPV5 via the TRPV5 N- Figure 1A ). PCR analysis performed on cDNA from HEK293 cells using specific β-gal primers showed that HEK293 cells endogenously express β-gal ( Figure 1B ). Because exogenous galactose can inhibit endogenous β-gal activity, it may reduce TPRV5 activity. The addition of D(+)-galactose (2-3 µg/mL, 16 h) significantly inhibited 45 Ca 2+ uptake of TRPV5, but not that of TRPV5 N358Q ( Figure   1C ). β-gal hydrolyses both end-standing β(1-3) and β(1-4) linkages (Varki et al. 2009 ).
To clarify the mechanism of β-gal-stimulated TRPV5 activity, the effect of enzymes specific for β(1-3) (β(1-3)-gal, 20 mU/mL) or β(1-4) linkages (β(1-4)-gal, 20 mU/mL) were investigated. While the β(1-3)-gal enzyme did not stimulate 45 Ca 2+ uptake, β(1-4)-gal significantly enhanced TRPV5-mediated Ca 2+ uptake in a similar manner as β-gal ( Figure 1D ). Importantly, β(1-4)-gal treatment did not alter the expression levels of TRPV5 protein ( Figure 1D ). TRPV5 N358Q was insensitive to both β(1-3)-gal and β(1-4)-gal treatment ( Figure 1E ). Moreover, an long term treatment with β(1,4)-gal was necessary in order to detect the stimulation ( Figure 1F ).
β(1-4)-gal stimulates the activity of TRPV5
To validate the specificity of the β(1-4)-gal-mediated TRPV5 stimulation, the function of TRPV5 and TRPV5 N358Q was studied by whole-cell patch clamp measurements.
Using Na + as the main charge carrier, Ca
2+
-sensitive inwardly rectifying currents were observed in cells expressing TRPV5 or TRPV5 N358Q (Figure 2A ). The shape of the EGTA-sensitive current-voltage curve was similar for TRPV5 and TRPV5 N358Q ( Figure   2B -C). Pre-treatment with β(1-4)-gal significantly increased the current density of TRPV5-expressing cells at -90 mV (p<0.05) with a trend for increase at negative membrane voltages (-70 to -100 mV), but did not affect the current density of the TRPV5 N358Q mutant expressing cells ( Figure 2B -C) at all tested voltages. Further analysis revealed that the N358Q mutation did not alter the kinetics of channel opening or any other observable macroscopic parameters at -100 mV. Subsequently, cells expressing TRPV5 or TRPV5 N358Q were subjected to cell-attached patch clamp, as previously described (Nilius et al. 2000) . Using this approach, single-channel activity was detected for both TRPV5 and TRPV5 N358Q ( Figure 3A ). Detailed analysis revealed that the single-channel conductance ( Figure 3B ) and open probability ( Figure 3C ) were not different between TRPV5 and TRPV5 N358Q .
β(1-4)-gal promotes retention of TRPV5 at the plasma membrane
Live-cell TIRF-M was performed on cells expressing a Dendra-2-TRPV5 fusion protein as described previously (Gurskaya et al. 2006; Leunissen et al. 2013) , permitting the time-dependent visualization of channels situated in close vicinity to the plasma membrane (~70-100 nm). The Dendra2 proteins were photo-converted using a brief Figure   4B ). Dendra2-TRPV5 N358Q was subjected to an identical protocol. Under these conditions, the basal plasma membrane retention time increased, while β(1-4)-gal had no additional effect ( Figure 4C ).
β-gal is expressed in the proximal tubule and enhances

45
Ca 2+ transport in mice
DCT2/CNT
Immunoblot analysis indicated that β-gal was present in mouse urine ( Figure 5A ). In addition, tubular β-gal protein expression was present in kidney sections, with a stronger signal apparent on the apical side. Co-expression was not observed between TRPV5 (DCT2/CNT marker) or uromodulin (thick ascending limb (TAL) marker) and β-gal. However BCRP, a proximal tubule marker (Huls et al. 2008) , is coexpressed with β-gal ( Figure 5B ).
Kidneys obtained from mice expressing enhanced GFP (eGFP) under the TRPV5 gene promoter were utilised (Markadieu et al. 2012) to assess the effect of β-gal on Ca 2+ transport in a physiological setting. GFP-positive segments (DCT2/CNT) were sorted by COPAS (see Experimental procedures) and seeded on permeable transwell filters. After 7 days in culture, these DCT2/CNT primary cells developed a monolayer with a transepithelial resistance of 547 ± 37 cm 2 (n=33). The monolayers were treated apically with β(1-4)-gal for 16 h (32 mU/mL) while Forskolin, a known TRPV5 activator, was used as a positive control (van Baal et al. 1996; Hoenderop et al. 1998) . Forskolin stimulates the cAMP/PKA pathway resulting in TRPV5 phosphorylation and thereby increasing channel activity (Diepens et al. 2004; de Groot et al. 2009 ).
Transepithelial Ca 2+ transport was followed over time by supplying apical This study demonstrated that both TRPV5 N358Q and β(1-4)-gal-treated TRPV5 channels had increased plasma membrane stability without a significant change in their intrinsic biophysical properties. Furthermore, it showed that even though β(1-4)-gal could affect numerous glycoproteins, the effect on the Ca 2+ uptake is specific for TRPV5 as the TRPV5 N358Q expressing cells are not responsive to β(1-4)-gal treatment. Other members of the TRPV family have also been shown to present glycosylation-dependent regulation (H. Xu et al. 2006; Veldhuis et al. 2012 ). For instance, ablation of the unique N-glycan in TRPV4 enhanced plasma membrane abundance of the channel without affecting its function (H. Xu et al. 2006 ). In contrast, preventing glycosylation of TRPV1 at the residue N604 altered its ionic permeability and capsaicin sensitivity. However, the N-glycan-mediated alteration of plasma membrane stability of TRPV1 cannot be excluded due to the presence of multiple glycosylation sites in TRPV1 (Veldhuis et al. 2012) . Our findings suggest that the N358 residue does not take part in the gating or structural constituents of the pore of TRPV5. Moreover, mutational ablation of the TRPV5 N-glycan could reduce clathrin-mediated internalization, as previously suggested for sphingosine 1-phosphate receptor Edg-1 and the dendritic cell-specific intracellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) (Kohno et al. 2002; Torreno-Pina et al. 2014) . Further experiments studying the details of TRPV5 trafficking will be necessary to validate this hypothesis.
Extracellular galectins are glycan-binding proteins with high affinity for Nacetyllactosamine (LacNAc), a saccharide repeat of Gal-( -1,4)-GlcNAc units (Cooper 2002) . Galectin-1, -3, -8 and -9 are expressed in mammalian kidneys (Hughes 2002 ).
Galectin-mediated regulation of TRPV5 could be a new regulatory mechanism of Ca 2+ transport as previous reports have suggested that binding of galectin-1 and galectin-Furthermore, TRPV5 co-localized with galectin-3, but not with galectin-1 and TRPV5-mediated Ca 2+ uptake in HEK293 cells was stimulated by extracellular galectin-3 and galectin-1 (Cha et al. 2008; Leunissen et al. 2013) . Based on these findings, disruption of galectin binding by β(1,4)-gal treatment would decrease the TRPV5 activity.
However, it should be noted that β(1,4)-gal treatment will not modify LacNAc repeats if capped with sialic acids and capping with sialic acids only slightly influences galectin-3 binding to LacNAc repeats, as galectin-3 does not need an endstanding LacNAc repeat for binding (Ahmad et al. 2011) . Therefore, we propose that This disease is associated with renal Ca 2+ wasting, although the molecular mechanisms underlying these findings are not known. However, a compensatory upregulation of TRPV5 mRNA and protein levels have been observed in diabetic rats (Lee et al. 2006 ). Diabetes mellitus type 1 patients show elevated β-gal levels in blood as well as in urine, suggesting that β-gal upregulation may represent an additional mechanism of compensation to prevent renal Ca 2+ wasting (E. Kohler et al. 1979; Serrano et al. 1983) . Second, patients with a deficiency in β-gal expression commonly present skeletal anomalies (Oshima et al. 1991; Yoshida et al. 1992 ). GM1
gangliosidosis is associated with flattening of vertebral bodies, while Morquio B disease is associated with skeletal dysplasia. This phenotype is comparable to the TRPV5 -/-mice, which show significant alterations in bone structure . Future in vivo studies may substantiate the link between the observed phenotype in β-gal-diseased patients and TRPV5 dysregulation.
Materials and methods
DNA constructs
The pCINeo/IRES-GFP plasmid encoding TRPV5 was generated as described previously (van de Graaf et al. 2003) . The TRPV5 N358Q mutant was obtained by in vitro site-directed mutagenesis of wild type (wt)-TRPV5-pCINeo/IRES-GFP (Stratagene, La Jolla, CA, USA). The pcDNA3-Dendra2-HA-TRPV5 and pcDNA3-Dendra2-HA-TRPV5 N358Q vectors were generated as previously described (Leunissen et al. 2013) .
Mouse β-galactosidase (Biosource Bioscience LifeSciences, Cambridge, UK) was subcloned into the pCINeo/IRES-GFP vector using the XhoI and AscI restriction sites.
All constructs were verified using DNA sequencing.
Cell culture and transfections
HEK293 cells were grown in Dulbecco's modified eagle's medium (DMEM, Bio
Whittakker-Europe, Verviers, Belgium) containing 10% (v/v) fetal calf serum (PAA, Liz Australia), 2mM L-glutamine and 10 g/ml non-essential amino acids at 37 ºC in a humidity-controlled incubator with 5% (v/v) CO 2 . HEK293 cells were transiently transfected using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), or Polyethyleneimine (PEI) (Brunswig/PolySciences). Transfections were performed according to manufacturer's protocol. 
Immunoblotting and determination of protein concentration
TRPV5 protein expression was determined by 8 % (w/v) SDS-PAGE
Electrophysiology
Experiments were performed using an EPC-9 amplifier and the Patchmaster software (HEKA electronics, Lambrecht, Germany). The sampling interval was set to 200 ms for whole-cell recordings and 20 ms for single-channel recordings. Whole-cell recordings were acquired with a low-pass filter set at 3.6 kHz, while single-channel recordings had a low-pass filter set at 5 kHz. The electrical noise was reduced further using the Humbug 50/60 Hz noise eliminator (Quest Scientific, Vancouver, Canada).
Whole-cell patch clamp pipettes were pulled from thin-walled borosilicate glass (Harvard Apparatus, March-Hugstetten, Germany) and had resistances between 1 and 3 M when filled with the pipette solution. Series resistance compensation was set to 75-95% in all whole-cell experiments. Single-channel patch clamp pipettes were made of thick-walled borosilicate glass (Harvard Apparatus and World Precision Instruments) and had resistances between 8 and 11 M when filled with the pipette solution. Single-channel recordings were analyzed using the Qub software package (Milescu et al. 2000) . Three different extracellular solutions were used to obtain whole-cell recordings of TRPV5 activity. 
COPAS Sorting
Transgenic mice expressing eGFP under the control of the TRPV5 promoter were generated as described previously (Hofmeister et al. 2009; van der Hagen et al. 2014 ). Fluorescent DCT2/CNT tubules were isolated from transgenic animals, using for radioactivity using a liquid scintillation counter as previously described (de Groot et al. 2009 ).
Immunohistochemistry
Kidneys of wt C57BL/6N mice were harvested and fixed in 1% ( at Radboud University on January 7, 2016
